Acta Med. 2018, 61: 86-92
https://doi.org/10.14712/18059694.2018.123
Soluble Tumor Necrosis Factor (TNF)-Like Weak Inducer of Apoptosis (Tweak) Independently Predicts Subclinical Atherosclerosis in Behcet’s Disease
References
1. Semin Thromb Hemost 2015; 41: 621–8.
NV, Fernandez-Bello I, Lopez-Longo FJ, Jimenez-Yuste V. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behçet Disease.
2. Lupus 2005; 14: 723–6.
< F, Sarzi-Puttini P, Doria A, Boiardi L, Pipitone N, Salvarani C. Behçet’s disease and cardiovascular involvement. https://doi.org/10.1191/0961203305lu2208oa>
3. Cardiovasc J Afr 2014; 25: 63–6.
< Z, Karadag AS, Tasar M, Kalender M, Darcin OT. Behcet’s disease and cardiovascular involvement: our experience of asymptomatic Behcet’s patients. https://doi.org/10.5830/CVJA-2014-003>
<PubMed>
4. Semin Arthritis Rheum 2016; 45: 502–10.
< M, Ster IC, Ames PR. Subclinical atherosclerosis in Behcet’s disease: A systematic review and meta-analysis. https://doi.org/10.1016/j.semarthrit.2015.06.018>
5. Clin Rheumatol 2016; 35: 701–8.
< M, Yildiz A, Oylumlu M, et al. Novel markers of endothelial dysfunction and inflammation in Behçet’s disease patients with ocular involvement: epicardial fat thickness, carotid intima media thickness, serum ADMA level, and neutrophil-to-lymphocyte ratio. https://doi.org/10.1007/s10067-015-2907-0>
6. Cell 2005; 123: 931–44.
< H, Varfolomeev E, Kischkel F, et al. TWEAK attenuates the transition from innate to adaptive immunity. https://doi.org/10.1016/j.cell.2005.09.022>
7. Front Immunol 2014; 5: 50.
< T, Sajjad A, Engel FB. TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure. https://doi.org/10.3389/fimmu.2014.00050>
<PubMed>
8. Clin Immunol 2005; 117: 15–23.
< S, Creidy R, Varriale S, et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. https://doi.org/10.1016/j.clim.2005.06.005>
9. Cytokine 2007; 40: 1–16.
< LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/ Fn14 pathway in health and disease. https://doi.org/10.1016/j.cyto.2007.09.007>
10. Front Immunol 2013; 4: 489.
< D, Stephan D, Khrestchatisky M, Desplat-Jego S. Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases? https://doi.org/10.3389/fimmu.2013.00489>
<PubMed>
11. Front Immunol 2013; 4: 488.
< J, Chacon MR. TWEAK: A New Player in Obesity and Diabetes. https://doi.org/10.3389/fimmu.2013.00488>
<PubMed>
12. Arterioscler Thromb Vasc Biol 2007; 27: 916–22.
< LM, Martín-Ventura JL, Munoz-Garcia B, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. https://doi.org/10.1161/01.ATV.0000258972.10109.ff>
13. Lancet 1990; 335: 1078–80.
for diagnosis of Behcet’s disease. International Study Group for Behcet’s Disease.
14. Rheumatology (Oxford) 1999; 38: 728–33.
< BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet’s disease: evaluation of a new instrument to measure clinical activity. https://doi.org/10.1093/rheumatology/38.8.728>
15. J Am Soc Nephrol 2001; 12(11): 2458–64.
FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients.
16. Clin Rheumatol 2012; 31(2): 335–9.4.
< C, Chen LL, Pan HF, Leng RX, Qin WZ, Ye DQ. Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus. https://doi.org/10.1007/s10067-011-1865-4>
17. Scand J Rheumatol 2008; 37: 173–8.
< MC, Chung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. https://doi.org/10.1080/03009740801898608>
18. Cytokine 2011; 53: 289–91.
< L, Shen H, Xiao W, Lu J. Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase- 3 serum levels. https://doi.org/10.1016/j.cyto.2010.12.003>
19. Cytokine 2011; 53: 295–300.
< ZC, Zhou QL, Li XZ, et al. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. https://doi.org/10.1016/j.cyto.2010.11.012>
20. Arthritis Res Ther 2011; 13: R51.
< AA, Smith MD, Crotti TN, et al. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. https://doi.org/10.1186/ar3294>
<PubMed>
21. PLoS One 2013; 8: e56830.
< T, Guo ZP, Li L, et al. TWEAK enhances E-selectin and ICAM- 1 expression, and may contribute to the development of cutaneous vasculitis. https://doi.org/10.1371/journal.pone.0056830>
<PubMed>
22. Folia Histochem Cytobiol 2009; 47: 465–9.
< M, Kowal K, Lapinska A, et al. Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. https://doi.org/10.2478/v10042-010-0028-9>
23. Mediators Inflamm 2002; 11: 87–93.
< C, Er H, Türköz Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease. https://doi.org/10.1080/09629350220131935>
<PubMed>
24. Arab J Nephrol Transplant 2012; 5: 27–32.
SB, El-demery AB, Ahmed AI, Abukhalil RE. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients.
25. Front Biosci 2004; 9: 2273–84.
< S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/ Fn14 in the pathogenesis of inflammation and systemic autoimmunity. https://doi.org/10.2741/1395>
26. Circ J 2004; 68: 396–9.
< SH, Kang YJ, Kim WJ, et al. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. https://doi.org/10.1253/circj.68.396>
27. Ren Fail 2013; 35: 77–81.
< O, Kismali E, Sisman AR, et al. The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients. https://doi.org/10.3109/0886022X.2012.734890>
28. BMC Nephrol 2013; 14: 144.
< K, Tonbul HZ, Erdur FM, et al. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. https://doi.org/10.1186/1471-2369-14-144>
<PubMed>
29. Int Urol Nephrol 2014; 46: 411–5.
< A, Akdoğan MF, Denizli N, et al. Soluble TWEAK levels are independently associated with coronary artery disease severity in patients with stage 2–3 kidney disease. https://doi.org/10.1007/s11255-013-0562-4>
30. Am J Physiol Endocrinol Metab 2013; 305: E101–12.
< A, Ceperuelo-Mallafre V, Chacon MR, et al. TWEAK prevents TNF-α-induced insulin resistance through PP2A activation in human adipocytes. https://doi.org/10.1152/ajpendo.00589.2012>
31. Eur J Clin Invest 2015; 45: 27–35.
< I, Llaurado G, Chacon MR, et al. Reduced circulating levels of TWEAK are associated with gestational diabetes mellitus. https://doi.org/10.1111/eci.12375>
32. Atherosclerosis 2008; 199: 440–4.
< S, Ziegelmeier M, Bachmann A, et al. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. https://doi.org/10.1016/j.atherosclerosis.2007.10.022>
33. Front Biosci 2007; 12: 3648–55.
< LM, Martín-Ventura JL, Munoz-Garcia B, et al. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. https://doi.org/10.2741/2341>
34. J Biol Chem 2009; 284: 4439–50.
< H, Mittal A, Paul PK, et al. Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-kappaB-inducing kinase and p38 mitogen-activated protein kinase: a potential role of MMP-9 in myopathy. https://doi.org/10.1074/jbc.M805546200>
<PubMed>
35. Spine (Phila Pa 1976) 2008; 33: 2489–94.
< M, Ohba T, Ando T, et al. Mechanism of signal transduction in tumor necrosis factor-like weak inducer of apoptosis-induced matrix degradation by MMP-3 upregulation in disc tissues. https://doi.org/10.1097/BRS.0b013e318186b343>
36. Cardiovasc Res 2011; 89: 225–33.
< B, Madrigal-Matute J, Moreno JA, et al. TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. https://doi.org/10.1093/cvr/cvq278>
37. Front Immunol 2014; 5: 3.
< LM. TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. https://doi.org/10.3389/fimmu.2014.00003>
<PubMed>
38. Arch Med Res 2011; 42: 398–404.
< M, Frigui M, Ben Mahfoudh K, et al. Intima-media thickness of carotid artery in patients with Behçet’s disease. https://doi.org/10.1016/j.arcmed.2011.08.006>
39. Angiology 2015; 66: 291–6.
< C, Balta S, Balta I, et al. Neutrophil-lymphocyte ratio and carotid- intima media thickness in patients with Behçet disease without cardiovascular involvement. https://doi.org/10.1177/0003319714527638>
40. J Am Heart Assoc 2016; 5: e003529.
< JP, Girerd N, Bozec E, et al. Intima-Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Population-Based Cohort (STANISLAS Cohort Study). https://doi.org/10.1161/JAHA.116.003529>
<PubMed>
41. Leonardo NM, McNeil J. Behcet’s Disease: Is There Geographical Variation? A Review Far from the Silk Road. Int J Rheumatol 2015; 2015: 945262.
42. Int J Dermatol 1986; 25: 235–9.
< AU, Yazici H, Yurdakul S, et al. Behçet’s disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. https://doi.org/10.1111/j.1365-4362.1986.tb02232.x>